Science | 09 January 2025 | News
Specific brain regions drive chemotherapy-induced pain response: IISc study
Chronic physical pain can be debilitating, but feelings of stress, fear, and hunger can sometimes suppress pai...Read more
Telangana | 31 December 2024 | Interviews
What key initiatives and strategic changes is the Telangana government implementing to attract investments in ...Read more
MedTech | 13 January 2025 | News
Stryker launches Insignia Hip Stem for total hip and hemiarthroplasty procedures in India
Stryker, a global leader in medical technologies, has announced the launch of its Insignia Hip Stem in In...Read more
West Bengal | 08 January 2025 | News
Global Cloud Cayr launches health management services in Kolkata
Global Cloud Cayr (GCC), an innovative healthcare startup founded by an international team of doctors and...Read more
Supplier | 09 January 2025 | News
Bruker launches infrared imaging microscope for pharma and life science research
US-based Bruker Corporation has announced the launch of the LUMOS II ILIM, a quantum cascade la...Read more
People | 09 January 2025 | News
Medanta appoints leading urologist Dr Sanjay Gogoi as Chairman of Renal Care Institute
Reinforcing its leadership in advanced kidney care and transplantation, Medanta has appointed globally renowne...Read more
Uttar Pradesh | 08 January 2025 | News
Chandigarh University announces establishment of AI-enabled futuristic campus in Lucknow
Chandigarh University (CU) has announced the establishment of the first-of-its-kind A...Read more
Text blogs | 31 December 2024 | Views
Key Skills & Salary Trends in Healthcare & Pharma for 2025
Evolving Skillsets The healthcare and pharmaceutical industries are undergoing profound transformations...Read more
Indian Pharma Hits R&D Salvo
Pharma companies are constantly on the quest to discover the next big game-changer drug or therapeutic by leveraging the latest, cutting-edge innovation. While it is notable that biopharma companies eased up on their research and development (R&D) spending in FY 2022-23 after the world was hit by COVID-19- induced economic slowdown, the budget for R&D has witnessed a steady increase. Departing a bit from their traditional drug portfolios, companies are increasingly focusing on R&D in nextgeneration therapies to drive innovation, particularly in complex generics, biosimilars, cell and gene therapies and novel drug delivery systems.
For Feedback, please email us at: communications@mmactiv.com